Farrukh Tasnim Shah

Dr. Farrukh Tasnim Shah

NHS Blood and Transplant
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Blood Reviews
Verified
Journal Article
Open access
FSFarrukh Tasnim Shah
Farrukh Tasnim Shah
FSFarzana Sayani
Farzana Sayani
STSara Trompeter
Sara Trompeter
EDEmma Drasar
Emma Drasar
APAntonio Piga
Antonio Piga
Patients with β-thalassemia major (BTM) require regular blood transfusions, supported by appropriate iron chelation therapy (ICT), throughout their life. β-thalassemia is a global disease that is most highly prevalent in Southeast Asia, Africa, and Mediterranean countries. However, the global distribution of patients with β-thalassemia is changing due to population migration, and Northern European countries now have significant thalassemia populations. Globally, many patients with BTM have limited access to regular and safe blood transfusions. A lack of voluntary nonremunerated blood donors, poor awareness of thalassemia, a lack of national blood policies, and fragmented blood services contribute to a significant gap between the timely supply of, and demand for, safe blood. In many centers, there is inadequate provision of antigen testing, even for common red cell antigens such as CcEe and Kell. Policies to raise awareness and increase the use of red blood cell antigen testing and requesting of compatible blood in transfusion centers are needed to reduce alloimmunization (the development of antibodies to red blood cell antigens), which limits the effectiveness of transfusions and the potential availability of blood. Patients with BTM are also at risk of transfusion-transmitted infections unless appropriate blood screening and safety practices are in place. Hence, many patients are not transfused or are undertransfused, resulting in decreased health and quality-of-life outcomes. Hemovigilance, leukoreduction, and the ability to thoroughly investigate transfusion reactions are often lacking, especially in resource-poor countries. ICT is essential to prevent cardiac failure and other complications due to iron accumulation. Despite the availability of potentially inexpensive oral ICT, a high proportion of patients suffer complications of iron overload and die each year due to a lack of, or inadequate, ICT. Increased awareness, training, and resources are required to improve and standardize adequate blood transfusion services and ICT among the worldwide population of patients with BTM. ICT needs to be available, affordable, and correctly prescribed. Effective, safe, and affordable new treatments that reduce the blood transfusion burden in patients with β-thalassemia remain an unmet need.

6 October 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
FSFarrukh Tasnim Shah
Farrukh Tasnim Shah
JPJohn B. Porter
John B. Porter
NSNandini Sadasivam
Nandini Sadasivam
BKBanu Kaya
Banu Kaya
JMJames C. Moon
James C. Moon
SPShivan Pancham
Shivan Pancham
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

Verified
Journal Article
Open access
PDF file
FSFarrukh Tasnim Shah
Farrukh Tasnim Shah
KHKrystal Huey
Krystal Huey
SDSohan Deshpande
Sohan Deshpande
MTMonica Turner
Monica Turner
MCMadhura Chitnis
Madhura Chitnis
EOEsther Natalie Oliva
Esther Natalie Oliva
Among the difficulties of living with β-thalassemia, patients frequently require blood transfusions and experience iron overload. As serum ferritin (SF) provides an indication of potential iron overload, we conducted a systematic literature review (SLR) to assess whether SF levels are associated with clinical and economic burden and patient-reported outcomes (PROs). The SLR was conducted on 23 April 2020 and followed by analysis of the literature. Dual-screening was performed at the title, abstract, and full-text levels using predefined inclusion and exclusion criteria. Ten studies identified by the SLR were eligible for inclusion in the analysis. Seven studies were conducted in Europe, and most were prospective or retrospective in design. The patient populations had a median age of 20.7–42.6 years, with a percentage of men of 38–80%. Sparse data were found on the correlation between SF levels and mortality, and hepatic, skeletal, and cardiac complications; however, in general, higher SF levels were associated with worsened outcomes. The bulk of the evidence reported on the significant association between higher SF levels and endocrine dysfunction in its many presentations, including a 14-fold increase in the risk of diabetes for patients with persistently elevated SF levels. No studies reporting data on PROs or economic burden were identified by the SLR. SF levels provide another option for prognostic assessment to predict a range of clinical outcomes in patients with β-thalassemia.

19 February 2014 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
AAAi Leen Ang
Ai Leen Ang
PTPloutarchos Tzoulis
Ploutarchos Tzoulis
EPEmma Prescott
Emma Prescott
BDBernard A. Davis
Bernard A. Davis
MBMaria Barnard
Maria Barnard
FSFarrukh Tasnim Shah
Farrukh Tasnim Shah

8 September 2021 in eJHaem
Verified
Journal Article
Open access
PDF file
FSFarrukh Tasnim Shah
Farrukh Tasnim Shah
PTPaul Telfer
Paul Telfer
MVMark Velangi
Mark Velangi
SPShivan Pancham
Shivan Pancham
RWRobert Wynn
Robert Wynn
KRKate Ryan
Kate Ryan
Objectives: We evaluated routine healthcare management, clinical status and patient‐ and carer‐reported outcomes in UK paediatric and adult patients with transfusion‐dependent β‐thalassaemia (TDT).Methods: A multi‐centre, observational mixed‐methodology study evaluated 165 patients (50% male; median age 24.1 [interquartile range (IQR)] 11.8–37.2] years) from nine UK centres.Results: Patients had a mean of 13.7 (standard deviation [SD] ±3.2) transfusion episodes/year (mean retrospective observation period 4.7 [±0.7] years). The median (IQR) for iron overload parameters at the last assessment during the observation period were: serum ferritin (n = 165) 1961.0 (1090.0–3003.0) μg/L (38% > 2500 μg/L); R2 liver iron (n = 119) 5.4 (2.9–11.6) mg/g (16% ≥15 mg/g); T2* cardiac iron (n = 132) 30.3 (22.0–37.1) ms (10% < 10 ms). All patients received ≥1 iron chelator during the observation period; 21% received combination therapy. Patients had a mean of 7.8 (±8.1) non‐transfusion‐related hospital attendances or admissions/year. Adult patients’ mean EQ‐5D utility score was 0.69 (±0.33; n = 94 [≥16 years]) and mean Transfusion‐dependent quality of life score was 58.6 (±18.4; n = 94 [≥18 years]). For Work Productivity and Activity impairment, mean activity impairment for patients ≥18 years (n = 88) was 48% (±32%) and for carers (n = 29) was 28% (±23%).Conclusions: TDT presents significant burden on patients, carers and healthcare resources.

1 June 2022 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
CEChinea Eziefula
Chinea Eziefula
FSFarrukh Tasnim Shah
Farrukh Tasnim Shah
KAKofi A Anie
Kofi A Anie
Thalassaemia is one of the commonest inherited genetic disorders world-wide with around 25,000 births of the most severely affected transfusion dependent children annually. Patients with transfusion dependent thalassaemia require regular blood transfusions to maintain life but because of this will develop iron overload. To remove the excess iron, patients are required to take iron chelation therapy (ICT). ICT requires lifelong adherence to treatment to prevent end organ damage from developing. Many of these preventable complications make adherence to therapy more complex for patients. In this review, we focus on two commonly encountered patient scenarios and discuss how different psychological models and a relational theory can be used to understand and support adherence to treatment.